Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 5.85% is 112% above its 5-year average of -49.50%, near the high end of its 5-year range (-96.99%–5.85%).
As of the fiscal period ended Tuesday, June 30, 2026. 140.24% above its 12-month average of -14.54%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 5.85%.
RETURN ON INVESTED CAPITAL (ROIC)
5.85%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-14.54%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-49.34%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-49.50%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-49.07%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+140.24%
CURRENT VS 3Y AVG
+111.86%
CURRENT VS 5Y AVG
+111.82%
CURRENT VS 10Y AVG
+111.92%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.41%
median of 337 covered companies
CURRENT VS SECTOR MEDIAN
+124.99%
vs the sector median at left
Ascendis Pharma A/S
Market Cap
$14.16B
Return on Invested Capital (ROIC)
5.85%
TTM Avg
-14.54%
3Y Avg
-49.34%
5Y Avg
-49.50%
Market Cap
$14.64B
Return on Invested Capital (ROIC)
-14.34%
TTM Avg
-61.05%
3Y Avg
-59.83%
5Y Avg
-54.60%
Market Cap
$14.79B
Return on Invested Capital (ROIC)
37.87%
TTM Avg
23.96%
3Y Avg
17.78%
5Y Avg
13.78%
Market Cap
$14.97B
Return on Invested Capital (ROIC)
7.72%
TTM Avg
5.13%
3Y Avg
6.33%
5Y Avg
6.84%
Market Cap
$13.19B
Return on Invested Capital (ROIC)
0.87%
TTM Avg
11.88%
3Y Avg
15.16%
5Y Avg
18.34%
Market Cap
$15.24B
Return on Invested Capital (ROIC)
15.85%
TTM Avg
12.30%
3Y Avg
11.68%
5Y Avg
11.64%
Market Cap
$12.95B
Return on Invested Capital (ROIC)
-62.14%
TTM Avg
-81.52%
3Y Avg
-104.01%
5Y Avg
-93.27%
Market Cap
$12.89B
Return on Invested Capital (ROIC)
4.80%
TTM Avg
6.92%
3Y Avg
6.32%
5Y Avg
7.02%
Market Cap
$12.52B
Return on Invested Capital (ROIC)
-1.61%
TTM Avg
-0.86%
3Y Avg
-2.74%
5Y Avg
0.22%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ascendis Pharma A/S (ASND) | $14.16B | 5.85% | -14.54% | -49.34% | -49.50% |
| Tempus AI, Inc. (TEM)vs › | $14.64B | -14.34% | -61.05% | -59.83% | -54.60% |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 37.87% | 23.96% | 17.78% | 13.78% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.97B | 7.72% | 5.13% | 6.33% | 6.84% |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 0.87% | 11.88% | 15.16% | 18.34% |
| Solventum Corporation (SOLV)vs › | $15.24B | 15.85% | 12.30% | 11.68% | 11.64% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | -62.14% | -81.52% | -104.01% | -93.27% |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 4.80% | 6.92% | 6.32% | 7.02% |
| Baxter International Inc. (BAX)vs › | $12.52B | -1.61% | -0.86% | -2.74% | 0.22% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 8.48% | 7.10% | 4.92% | 2.27% |
ROIC
5.9%
ROE
53.0%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | 5.85% |
| 2026-03-31 | -0.55% |
| 2025-12-31 | -17.83% |
| 2025-09-30 | -21.20% |
| 2025-06-30 | -38.95% |
| 2025-03-31 | -50.37% |
| 2024-12-31 | -38.35% |
| 2024-09-30 | -43.80% |
| 2024-06-30 | -96.99% |
| 2024-03-31 | -81.44% |
| 2023-12-31 | -87.34% |
| 2023-09-30 | -85.71% |
| 2023-06-30 | -84.79% |
| 2023-03-31 | -70.21% |
| 2022-12-31 | -59.26% |
| 2022-09-30 | -49.68% |
| 2022-06-30 | -41.31% |
| 2022-03-31 | -36.76% |
| 2021-12-31 | -46.60% |
| 2021-09-30 | -40.83% |
| 2021-06-30 | -53.41% |
| 2021-03-31 | -42.86% |
| 2020-12-31 | -33.83% |
| 2020-09-30 | -29.47% |
| 2020-06-30 | -53.73% |
| 2020-03-31 | -42.39% |
| 2019-12-31 | -35.91% |
| 2019-09-30 | -29.38% |
| 2019-06-30 | -25.80% |
| 2019-03-31 | -24.63% |
| 2018-12-31 | -56.75% |
| 2018-09-30 | -50.73% |
| 2018-06-30 | -44.27% |
| 2018-03-31 | -34.32% |
| 2017-12-31 | -57.25% |
| 2017-09-30 | -47.67% |
| 2017-06-30 | -67.08% |
| 2017-03-31 | -51.60% |
| 2016-12-31 | -43.28% |
| 2016-09-30 | -86.41% |
| 2016-06-30 | -59.62% |
| 2016-03-31 | -50.08% |
| 2015-12-31 | -35.13% |
| 2015-09-30 | -26.66% |
| 2015-06-30 | -22.41% |
| 2015-03-31 | -14.10% |
| 2014-12-31 | -27.16% |
| 2014-09-30 | -106.80% |
| 2014-06-30 | 18.18% |
| 2013-12-31 | 71.31% |
